[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR096709A1 - Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) - Google Patents

Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)

Info

Publication number
AR096709A1
AR096709A1 ARP140102374A ARP140102374A AR096709A1 AR 096709 A1 AR096709 A1 AR 096709A1 AR P140102374 A ARP140102374 A AR P140102374A AR P140102374 A ARP140102374 A AR P140102374A AR 096709 A1 AR096709 A1 AR 096709A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
aromatic
nr8r9
heterocyclyl
Prior art date
Application number
ARP140102374A
Other languages
English (en)
Inventor
Miguel Vela-Hernndez Jos
Merlos-Roca Manuel
Manuel Baeyens-Cabrera Jos
Miguel Cendn-Martnez Cruz
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR096709A1 publication Critical patent/AR096709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente se refiere al uso de un ligando sigma, particularmente un ligando sigma de fórmula (1) para prevenir y/o tratar dolor asociado a cistitis intersticial / síndrome de dolor vesical (CI / SDV). Reivindicación 4: Ligando sigma según una cualquiera de las reivindicaciones 1 a 3, que tiene la fórmula general (1), en la que R se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R² se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R³ y R⁴ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno, o junto con el fenilo forman un sistema de anillos condensados opcionalmente sustituido; R⁵ y R⁶ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno, o juntos forman, con el átomo de nitrógeno al que están unidos, un grupo heterociclilo sustituido o no sustituido, aromático o no aromático; n se selecciona de 1, 2, 3, 4, 5, 6, 7 y 8; t es 0, 1 ó 2; R⁸ y R⁹ se seleccionan cada uno independientemente de hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, aromático o no aromático, alcoxilo sustituido o no sustituido, ariloxilo sustituido o no sustituido y halógeno; o una sal, isómero, profármaco o solvato farmacéuticamente aceptable del mismo.
ARP140102374A 2013-06-26 2014-06-24 Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) AR096709A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382246.0A EP2818166A1 (en) 2013-06-26 2013-06-26 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)

Publications (1)

Publication Number Publication Date
AR096709A1 true AR096709A1 (es) 2016-01-27

Family

ID=48700506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102374A AR096709A1 (es) 2013-06-26 2014-06-24 Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)

Country Status (19)

Country Link
US (1) US20160151377A1 (es)
EP (2) EP2818166A1 (es)
JP (1) JP2016523276A (es)
KR (1) KR20160023839A (es)
CN (1) CN105377257A (es)
AR (1) AR096709A1 (es)
AU (1) AU2014301220A1 (es)
BR (1) BR112015032343A8 (es)
CA (1) CA2916568A1 (es)
HK (1) HK1221656A1 (es)
IL (1) IL243362A0 (es)
MA (1) MA38711A1 (es)
MX (1) MX2015017761A (es)
PH (1) PH12015502815A1 (es)
RU (1) RU2016102149A (es)
SG (1) SG11201510408XA (es)
TN (1) TN2015000558A1 (es)
TW (1) TWI629984B (es)
WO (1) WO2014207024A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US20160310501A1 (en) * 2013-12-17 2016-10-27 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
MA39147B1 (fr) 2013-12-17 2019-12-31 Esteve Labor Dr Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002315814B2 (en) * 2001-07-10 2007-05-31 Astellas Pharma Inc. Medicinal composition for treatment of interstitial cystitis
CA2576144C (en) 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
WO2007025613A2 (en) * 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
US8202872B2 (en) * 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
NZ618795A (en) * 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain

Also Published As

Publication number Publication date
IL243362A0 (en) 2016-02-29
US20160151377A1 (en) 2016-06-02
RU2016102149A (ru) 2017-08-02
MA38711A1 (fr) 2017-12-29
CN105377257A (zh) 2016-03-02
EP2818166A1 (en) 2014-12-31
PH12015502815A1 (en) 2016-03-21
MX2015017761A (es) 2016-07-06
BR112015032343A8 (pt) 2018-01-23
RU2016102149A3 (es) 2018-05-25
HK1221656A1 (zh) 2017-06-09
JP2016523276A (ja) 2016-08-08
WO2014207024A1 (en) 2014-12-31
TWI629984B (zh) 2018-07-21
SG11201510408XA (en) 2016-01-28
TN2015000558A1 (en) 2017-04-06
CA2916568A1 (en) 2014-12-31
EP3013338A1 (en) 2016-05-04
BR112015032343A2 (pt) 2017-09-26
KR20160023839A (ko) 2016-03-03
AU2014301220A1 (en) 2016-02-18
TW201536295A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
AR101638A1 (es) Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR084730A1 (es) Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos
AR082441A1 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
AR101637A1 (es) Combinaciones de gabapentinoides y ligandos de receptores sigma
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR086632A1 (es) Ligandos sigma para la prevencion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia
AR109595A1 (es) Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR096748A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
MX2016012984A (es) Derivados indol para uso en medicina.
AR101600A1 (es) COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53
AR089175A1 (es) Inhibidores de pak para el tratamiento de trastornos de proliferacion celular
AR081369A1 (es) Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR101177A1 (es) Inhibidores de la syk
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure